Unlocking the Next
Chapter of Kidney Care
Meet the Expert Series: Video On Demand-Dr. Brendon Neuen
What is the benefit in All cause hospitalization of Empagliflozin in the A1 and A2 subpopulation?
Related Videos
1:15
EK22||What is the benefit observed among Asian patients included in EMPAKIDNEY based on the Primary Outcome of Composite of Kidney Disease Progression and CV Death?
2:35
EK22||When is the best time to initiate SGLT2i in CKD patients?
2:43
EK22||What was the Benefit observed of the use of Empagliflozin in T2D patients with CKD based on ERO and now EMPAKIDNEY?
2:32
EK22||What is the Impact in the composite of Kidney Disease Progression and CV Death in CKD patients based on Albuminuric status A1, A2, and A3?
Document ID: SC-ASK-00301